By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Japanese reagent and medical device firm Kyowa Medex today announced regulators in Japan have approved two companion diagnostics for a drug targeting adult T-cell leukemia-lymphoma (ATL).

The Ministry of Health, Labour, and Welfare approved Kyowa's Poteligeo Test IHC and Poteligeo Test FCM for Kyowa Hakko Kirin's Poteligeo (mogamulizumab) injection, a therapeutic antibody that was also approved by MHLW today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The ancestors of the Arizona bark scorpion and other scorpions and spiders underwent whole-genome duplication, KJZZ reports.

A cryptographic approach could help researchers keep genomic data private while researchers analyze it, Scientific American reports.

Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.

In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.